Nektar says rezpegaldesleukin shows early biomarker response in Phase 2b atopic dermatitis study
NKTR•Nektar reported early biomarker changes in its Phase 2b REZOLVE-AD study of rezpegaldesleukin, with shifts emerging within the first weeks of dosing and the company planning to advance the program into Phase 3.
1. Early study findings
Nektar disclosed new biomarker results from its Phase 2b REZOLVE-AD study of rezpegaldesleukin in moderate-to-severe atopic dermatitis. Presented at the EADV Congress 2026, the findings showed early biological activity consistent with the drug’s regulatory T-cell mechanism. Early molecular shifts tracked with later clinical improvement in treated patients, and the results underpin the company’s plan to advance the program into Phase 3 development.
